In the News | Friends of Cancer Research

You are here

In the News

November 19, 2018
Executive Summary CBER Director Peter Marks says the "half-life" for the existing six gene therapy guidances likely is two to three years due to the fast pace of scientific discovery. Genetic... Read more
November 19, 2018
When President Donald Trump rolled out an ambitious pilot program to lower the costs of physician-administered drugs in late October, policy experts expected the same swift condemnation Congress and... Read more
November 10, 2018
In an effort to determine best practices and ensure consistent clinical interpretation of tumor mutational burden ( TMB) assessment for cancer patients, a group of diagnostic test partners conducted... Read more
November 6, 2018
Results to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting November 6, 2018 - Washington, DC – Friends of Cancer Research (Friends) is pleased to announce that... Read more
November 5, 2018
In a group of sponsored presentations at last week's annual meeting of the Association for Molecular Pathology, Thermo Fisher Scientific product users reported on their experiences in a variety of... Read more
October 30, 2018
I am a big proponent of clinical trials. I think everyone should have access to them and any trial that they qualify for should be offered – regardless of whether or not I think they are “appropriate... Read more
October 25, 2018
Next-generation sequencing is used with increasing frequency to provide essential information about a patient’s diagnosis and treatment. In recent months, the U.S. Food and Drug Administration (FDA)... Read more
October 25, 2018
Friends of Cancer Research (Friends) recognized Senators Orrin Hatch (R–UT) and Michael Bennet (D–CO) for responding to a recently identified public health issue and proposing a solution to an issue... Read more
October 25, 2018
The Friends of Cancer Research (Friends) recently announced the launch of phase II of its tumor mutational burden Harmonization Project, as the research team finalizes data collected from phase I in... Read more
October 17, 2018
On July 9, 2012, officials signed the Food and Drug Administration Safety and Innovation Act (FDASIA) which had a section within it that established a new designation—the Breakthrough Therapy... Read more

Pages